Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 2301 to 2310 of 2586 total matches.
Prosthetic Heart Valves
The Medical Letter on Drugs and Therapeutics • Aug 20, 2012 (Issue 1397)
The Medical Letter®
On Drugs and Therapeutics
Volume 54 (Issue 1397)
August 20, 2012 ...
Prosthetic heart valves have been used effectively in
patients with mitral and aortic valvular heart disease
for more than 50 years, but no replacement valve
developed to date is suitable for all types of patients.
In Brief: New Polio Vaccination Guidance for Travelers
The Medical Letter on Drugs and Therapeutics • Sep 01, 2014 (Issue 1450)
Letter®
on Drugs and Therapeutics
Objective Drug Reviews Since 1959
Volume 56 September 1, 2014 ...
Wild poliovirus has circulated during the previous 12 months in Cameroon, Equatorial Guinea, Ethiopia, Iraq, Israel (also the West Bank and Gaza), Somalia, and Syria, as well as in those countries where polio is still endemic (Afghanistan, Nigeria, and Pakistan). The World Health Organization (WHO) has declared a public health emergency related to the possible spread of polio from affected countries. In response, the Centers for Disease Control and Prevention (CDC) has issued interim guidance for US residents planning travel to and from these countries.Vaccine Recommendations – All travelers...
In Brief: New Warnings for Janus Kinase Inhibitors
The Medical Letter on Drugs and Therapeutics • Oct 04, 2021 (Issue 1634)
skin cancer).1
1. FDA Drug Safety Communication. FDA requires warnings about
increased risk ...
The FDA has required updates to the boxed warnings
in the labeling of the Janus kinase (JAK) inhibitors
tofacitinib (Xeljanz, Xeljanz XR), baricitinib (Olumiant),
and upadacitinib (Rinvoq) describing increased risks
of major adverse cardiovascular events, malignancy,
thrombosis, and death with their use. The new warnings
were prompted by the results of a postmarketing safety
trial with tofacitinib and were added to the labels of
baricitinib and upadacitinib based on the presumption
of a class effect. The tofacitinib package insert had
contained a boxed warning about an increased...
COVID-19 Update: Bivalent Pfizer and Moderna Vaccines Authorized for Children ≥6 Months Old (Online Only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
. COVID update: Bivalent vaccine booster doses authorized for
children ≥5 years old. Med Lett Drugs Ther ...
The FDA has expanded its Emergency Use
Authorizations (EUAs) for the COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) to permit use of the bivalent
formulations of these products (containing mRNA
from the original and BA.4/5 Omicron strains of
SARS-CoV-2) in children as young as 6 months.
The bivalent Pfizer vaccine is authorized for use as
the final dose of a 3-dose primary series in children
6 months to 4 years old. The bivalent Moderna
vaccine is authorized for use as a booster dose in
children 6 months to 5 years old who completed
a primary...
COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
. Med Lett
Drugs Ther 2021; 63:113.
3. RECOVERY Collaborative Group. Tocilizumab in patients
admitted ...
The interleukin-6 (IL-6) receptor antagonist
tocilizumab (Actemra – Genentech) has been
approved by the FDA for IV treatment of COVID-19
in hospitalized adults who are receiving a systemic
corticosteroid and require supplemental oxygen,
mechanical ventilation, or extracorporeal membrane
oxygenation (ECMO). Tocilizumab was previously
available for this indication under an Emergency
Use Authorization (EUA); it remains available under
an EUA for treatment of children 2-17 years old
who are hospitalized with COVID-19 and require
oxygen support.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e9 doi:10.58347/tml.2023.1667d | Show Introduction Hide Introduction
In Brief: New FDA Warning of Pulmonary Aspiration with GLP-1 Receptor Agonists
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024 (Issue 1718)
have been published.1 Randomized, controlled
trials evaluating the risk of pulmonary aspiration with
these drugs ...
The package inserts of the GLP-1 receptor agonists
dulaglutide (Trulicity), exenatide (Byetta, Bydureon
BCise), liraglutide (Saxenda, Victoza), and semaglutide
(Ozempic, Rybelsus, Wegovy) and the dual glucosedependent
insulinotropic polypeptide (GIP)/GLP-1
receptor agonist tirzepatide (Mounjaro, Zepbound)
have been updated to include rare postmarketing
reports of pulmonary aspiration associated with their
use in patients undergoing elective surgery or other
procedures requiring general anesthesia or deep
sedation who had residual gastric contents despite
preoperative...
Med Lett Drugs Ther. 2024 Dec 23;66(1718):201-2 doi:10.58347/tml.2024.1718a | Show Introduction Hide Introduction
Omlyclo — An Omalizumab Biosimilar Interchangeable with Xolair
The Medical Letter on Drugs and Therapeutics • Apr 09, 2025 (Issue 5104)
-letter suffix -igec has no pronunciation or meaning; such
suffixes are added to biologic drugs ...
Omlyclo (omalizumab-igec; Celltrion), a biosimilar
product interchangeable with the recombinant anti-IgE monoclonal antibody Xolair, has been approved by
the FDA for same indications as Xolair (see Table 1).
Omlyclo is the first Xolair biosimilar to be approved in
the US.
Med Lett Drugs Ther. 2025 Apr 9;67(5104):1-2 doi:10.58347/tml.2025.5104a | Show Introduction Hide Introduction
Nitroglycerin Patches - Do They Work?
The Medical Letter on Drugs and Therapeutics • Jul 14, 1989 (Issue 796)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Transdermal nitroglycerin products commercially available in the USA are listed in the table below. These patches, which look like adhesive bandages, are often applied over the precordium, but they can be attached to any hairless area of the skin, except distal parts of the extremities. Individual patients vary in their absorption of nitroglycerin from the skin; the amounts delivered (the doses) are average figures.
Treatment of Hypothermia
The Medical Letter on Drugs and Therapeutics • Dec 23, 1994 (Issue 938)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
This winter physicians in many area may see patients suffering from hypothermia. Old age, lack of adequate housing, drug overdose and alcohol ingestion are often prediposing factors, but hypothermia also occurs in healthy young people after prolonged exposure to cold due to incapacitating trauma or cold water immersion. Hypothermia associated with exhaustionduring outdoor sports activities can occur even at relatively mild temperatures.
Umbilical Cord Blood for Bone Marrow Transplantation
The Medical Letter on Drugs and Therapeutics • Aug 16, 1996 (Issue 981)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
High-dose chemotherapy followed by bone marrow transplantation continues to be widely used in the treatment of malignant diseases (Medical Letter, 37:25, 1995). The source of the transplant has been autologous or allogeneic bone marrow or, more recently, stem and progenitor cells harvested from peripheral blood (Medical Letter, 37:71, 1995). Now, blood taken from the umbilical cord and placenta of a newborn infant is being tried as a source of cells to restore the bone marrow. A single collection of umbilical cord blood contains about as many progenitor cells as most autologous bone...